Controversies in the management of Pulmonary Embolism Joel Frankel, MD, FACP, FCCP Plantation General Hospital February 27, 2014 Clinical Case • 62 y.o. male presents to ED with 48 hours of worsening dyspnea after returning from a 3 day business trip to China • Vitals: BP 110/60, P 102, O2 sat 86% on RA • PE: Distended neck veins, RR w/o murmur, lungs clear, normal LE exam • D Dimer = 2496 • CT chest multiple thrombi in PA and dilated right ventricle • Management? Questions • Which form of Heparin? – Lovenox (1 mg/kg SC) – Unfractionated Heparin • (80 U/kg bolus; 18 U/kg drip) • Disposition – ICU – Medicine – Home Very Simple Goals • Remember atypical cases • Know why PE is missed • Make your chart bullet proof Why is the diagnosis delayed or missed? • • • • • • Not considering the diagnosis Presentation too atypical PE looks like many diseases The obvious miss Misinterpretation of studies Reliance on normal VS Elevated troponin • • • • Not just in MI !!! Myocarditis, tachycardia CHF, pericarditis, stroke, sepsis Pulmonary embolism Who do we miss the diagnosis in? • Obese females on OCP • Patients with medical comorbidities The Pulmonary Embolism Rule-Out Criteria (PERC) rule • Less than 2% chance of PE if clinician pre-test probability < 15% and all of the following: – – – – – – – – Age < 50 HR < 100 SpO2 > 96% No unilateral leg swelling No hemoptysis No recent trauma No h/o VTE/PE No OCP/exogenous estrogen use PE myths • All patients with PE are tachycardic – About 50% • Hypoxia is usually present • Most patients have risk factors – 20-25 % with risk factors • Classic presentation common Protective documentation • • • • • Thought process Leg exam, Homan’s sign Risk factor analysis Clinical gestalt Clinical decision rule The chart • • • • • Any patient with cardiopulmonary symptoms VTE risk factors Attention to the VS Leg exam Evidence that you thought about VTE Epidemiology • PE is common – 600,000-900,000 patients annually in US • PE has high morbidity and mortality – Mortality rate 10 – 17.5% overall – Likely responsible for over 50,000 deaths annually • Optimal management can improve these outcomes Questions for Discussion • Which is the optimal form of heparin to be used in the treatment of PE? • Do all patients with a new diagnosis of PE need to be admitted? • When are thrombolytics indicated in the management of PE? Which is the optimal form of heparin to be used in the treatment of PE? • Options for bridging anticoagulation in acute PE – Unfractionated heparin (UFH) – Low-molecular weight heparin (LMWH) • LMWH has multiple potential advantages over UFH • Use of LMWH for most patients is standard of care and recommended by multiple professional societies Evidence Supporting Use • Multiple RCTs have established efficacy and safety between LMWH and UFH for the treatment of PE – 3 month recurrence of VTE: 3.0% vs. 4.4 % (NS) – Major bleeding: 1.3% vs. 2.1 % (NS) Other Considerations • LMWH is renally cleared – use with caution with poor renal function • UFH preferred in hemodynamically unstable patients, especially if considering thrombolysis • No clear difference in efficacy or safetey when comparing once a day (1.5 mg/kg) vs. twice a day (1 mg/kg) dosing regimens Do all patients with a new diagnosis of PE need to be admitted? • Current standard of care is outpatient management for DVT • 30-40% of patients with DVTs have been found to have asymptomatic PEs • Although DVT and PE have different outcomes, they exist on the same spectrum of disease (VTE) • Likely there is some group of low-risk patients with PE that can be managed similarly to DVT Aujesky et al 2011 • Open-label, multi-center, international, non-inferiority, RCT • 339 adult patients with confirmed acute PE randomized to inpatient vs. outpatient management • Outpatients treated with 1 mg/kg LMWH BID until INR > 2.0 for > 2 days • Primary end-point was recurrent VTE • Secondary end-points included – Major bleeding – All cause mortality Inclusion/Exclusion Pulmonary Embolus Severity Score of I or II (<86 points) Points Assigned Age +1/year Male +10 Cancer +30 Heart Failure +10 Chronic Lung Disease +10 Pulse > 100 bpm +20 SPB < 100 mm Hg +30 RR > 30 bpm +20 T < 36 degrees C +20 Altered Mental Status +60 Oxygen Sat < 90% +20 • Patients excluded if any of the following – – – – – – – – – – – O2 sat < 90% SBP < 100 mmHg Chest pain requiring IV opiates Active bleeding Stroke within 10 days GI bleed within 14 days < 75,000 platelets Cr Clearance < 30 Extreme obesity (>150 kg) History of HIT Already being treated with oral anticoagulant – Any barriers to follow up Outcomes Outpatient Group (n=171) Inpatient Group (n=168) P-Value* Recurrent VTE 1 (0.6%) 0 (0%) 0.011 Major Bleeding 3 (1.8%) 0 (0%) 0.086 Mortality 1 (0.6%) 1 (0.6%) 0.005 Recurrent VTE 0 (0%) 0 (0%) 0.003 Major Bleeding 2 (1.2%) 0 (0%) 0.031 Mortality 0 (0%) 0 (0%) 0.003 90-day outcomes 14-day outcomes *P-value represents one-sided p-value for non-inferiority Erkens et al 2010 • Retrospective cohort study of consecutive patients with confirmed acute PE • Decision for outpatient treatment by treating physician based on hospital protocol – – – – SPB > 100 mmHG O2 sat > 92% No contraindication to LMWH Does not need admission for other reasons • Outpatients treated with LMWH • Patient followed-up at 14 days and 90 days Outcomes Outpatient Group (n=260) Inpatient Group (n=213) P-Value* Recurrent VTE 10 (3.8%) 10 (4.7%) 0.654 Major Bleeding 4 (1.5%) 17 (8.0%) 0.001 Readmission Rate 6 (2.3%) 11 (5.2%) 0.135 Mortality* 5 (5%) 57 (26.7%) <0.001 Recurrent VTE 1 (0.4%) 4 (1.9%) 0.180 Major Bleeding 0 (0%) 13 (6.1%) <0.001 Readmission Rate 4 (1.5%) 4 (1.9%) 1.0 Mortality* 1 (0.4%) 27 (12.7%) <0.001 90-day outcomes 14-day outcomes Are there other factors that can help risk stratify patients? • Troponin is a predictor of complicated clinical course or death – NPV for death 96-97% – NPV for complicated clinical course 92-94% • Pro-BNP is a predictor of mortality or adverse outcomes – NPV for death 99% – NPV for adverse outcome 95% • RV dysfunction on CT – NPV for PE related death 100% Take Home Message • Outpatient management of PE is not common practice currently, but feasible and safe in selected low-risk patients with acute PE • Standard of care is likely to shift in the near future given pressures to lower resource utilization • It is reasonable to offer outpatient management in the patient with low PE severity index, normal BP, normal O2 sats, normal EKG, normal troponin, normal pro-BNP, and no evidence of RV dysfunction • An informed discussion with the patient and careful documentation are necessary to attempt this approach When are thrombolytics indicated in the management of PE? • Risk of Bleeding with Thrombolysis in PE – Fatal Hemorrhage: 0.5 % – Intracranial Hemorrhage : 1.8-3.0 % – Major Hemorrhage: 9-13 % • Potential Benefits of Decreasing – Mortality – PE recurrence – Pulmonary Hypertension – In-Hospital Complications Differences in Outcomes • The mortality of patients with PE vary depending on the clinical circumstances – Cardiac Arrest: 66-95% – Massive PE: 22-53% – Submassive PE: 8-13% – Uncomplicated PE: 1-4% • The clinical circumstances should drive decision making with the use of thrombolytics Contraindications to Fibrinolytics • Active internal bleeding • Recent intracranial bleeding • Intracranial tumor or seizure history • Ischemic stroke within 2 months • Neurosurgery within the past 1 month • Surgery within the past 10 days • Puncture of noncompressible vessel within past 10 days • Trauma within 15 days • Uncontrolled HTN (SBP > 180; DBP > 100) • Hemorrhagic disorder or thrombocytopenia (<100,000) • Impaired hepatic or renal function • GI bleeding within 10 days • Pregnancy Cardiac Arrest • • • • 10-20% of all PE cases Dismal outcomes with 66-95% mortality No RCTs address this clinical scenario 3 major studies show significant increase in ROSC rate and trend toward increased survival in cardiac arrest • Overall bleeding complication rare is low when used in cardiac arrest • Multiple professional societies have supported use of thrombolytics in this clinical situation Bottiger et al 2001 • 90 patients with out-of-hospital cardiac arrest undergoing CPR without ROSC within 15 minutes • 40 patients received 50 mg tPA and 5000 U of heparin as bolus vs. 50 patients with standard ACLS – – – – ROSC: 68% vs. 58% (p=0.026) Survival to ICU admission: 58% vs. 44% (p=0.009) 24 hr Survival: 35% vs. 22% (p=0.171) Hospital Discharge: 15% vs. 8% (NS) • No CPR related bleeding complications Lederer et al 2001 • 324 patients with out-of-hospital cardiac arrest undergoing CPR • 108 received 50 mg tPA as bolus vs. 216 with standard ACLS (retrospective) – ROSC: 70.4% vs. 51.0% (p=0.001) – 24 hr Survival: 48.1% vs. 32.9% (p=0.003) – Hospital Discharge: 25% vs. 15.3% (p=0.048) • Bleeding complications low – ICH 0.9% vs. 0.9% (NS) – Major Hemorrhage 4.6% vs. 2.3% (NS) Bozeman et al 2006 • 163 patients in cardiac arrest undergoing CPR not responding to standard ACLS (prospective) • 50 received 30-50 mg tPA bolus vs. 113 controls with standard ACLS – ROSC: 26% vs. 12.4% (p=0.04) – Survival to ICU admission: 12% vs. 0% (p=0.0007) – 24 hr Survival: 4% vs. 0% (NS) – Hospital Discharge: 4%vs. 0% (NS) • 1 patient with ICH in tPA group (2%) Take Home Message • Although not definitely studied in patients with PE, likely benefit > risk to giving tPA in cardiac arrest with PE is suspected cause • Consider historical factors or bedside ultrasonography to guide decision making • When given, administer 50 mg tPA and 5000 U UFH as IV bolus • May repeat if no ROSC after 15 minutes • If ROSC occurs, start continuous infusion of UFH at 18 U/kg/hr Massive PE • 5% of all PE cases • Mortality 22-53% • 5 RCTs that included hemodynamically unstable patients suggest benefit • Meta-analysis of RCTs showed significant benefit • 2 retrospective studies show trend to benefit • Bleeding complications low in selected patients • Multiple professional societies recommend use of thrombolytics in this scenario Wan et al 2004 • Meta analysis of 11 RCTs comparing thrombolysis + heparin vs. heparin alone • Subgroup analysis of 5 RCTs that included hemodynamically unstable patients • 128 patients received thrombolysis, 126 received heparin alone • Efficacy Outcomes – Mortality: 6.2% vs. 12.7% (NS) – Recurrent PE: 3.9% vs. 7.1% (NS) – Recurrent PE or Death: 9.4% vs. 19% (p<0.05) • Bleeding outcomes: 21.9% vs. 11.9% (p=0.05) Take Home Message • Data regarding benefit not definitive, but benefit:risk ratio likely to support use in hemodynamically unstable patients • Consider use in select patients with CONFIRMED PE and hemodynamic instability keeping in mind patient risk for bleeding complications • When given, infuse 10 mg tPA as bolus followed by 90 mg infusion over 2 hours • Should be followed by 80 U/kg bolus of heparin followed by 18 U/kg/hr infusion Submassive PE • 23-40% of all PE cases • Increased mortality when compared to hemodynamically stable patients without RV dysfunction (9.3% vs. 0.4%) • Multiple studies have definitely shown improvement in hemodynamic or radiographic parameters, though improvement in clinical outcomes remains mixed Take Home Message • Treatment of patients with submassive PE with thrombolytics is highly controversial • Current evidence is conflicting and filled with multiple flaws • Use of thrombolytics in this situation does not carry overall support from professional societies and is not standard of care • Use of thrombolytics may be considered in select patients with support from sub-specialists Future Directions • The Pulmonary EmbolIsm THrOmbolysis (PEITHO) trial is a multicenter international RCT (double-blinded, placebo controlled) currently underway • Includes patients with – Confirmed acute PE – RV dysfunction on Echo or CT chest – Elevated Troponin • Treatment Protocol – Thrombolysis Group: tPA + UFH – Control Group: UFH only • Outcomes – Primary: Composite of Death or Hemodynamic Collapse < 7 days – Secondary: Death, Hemodynamic Collapse, Recurrent PE, ICH, Major Bleeding Follow-up on Initial Questions • Which is the optimal form of heparin to be used in the treatment of PE? – LMWH in most cases • Do all patients with a new diagnosis of PE need to be admitted? – There may be a group of very low risk patients that can be managed primarily as outpatients • When are thrombolytics indicated in the management of PE? – Clearly indicated in cardiac arrest from PE and massive PE without contraindication to fibrinolytics – Utility in submassive PE unclear – Not indicated in uncomplicated PE